- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05715931
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Hangzhou, Zhejiang, China, 310003
- Not yet recruiting
- The Second Affiliated Hospital, College of Medicine, Zhejiang University
-
Huzhou, Zhejiang, China, 313099
- Not yet recruiting
- Huzhou Central Hospital
-
Lishui, Zhejiang, China, 323000
- Not yet recruiting
- Lishui Central Hospital
-
Ningbo, Zhejiang, China, 315010
- Not yet recruiting
- Ningbo First Hospital
-
Ningbo, Zhejiang, China, 315048
- Not yet recruiting
- Ningbo medical center lihuili hospital
-
Ningbo, Zhejiang, China, 315099
- Not yet recruiting
- Ningbo second hospital
-
Taizhou, Zhejiang, China, 317099
- Not yet recruiting
- Taizhou Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF).
- The gender is not limited. Age: ≥ 18 years and ≤ 80 years old.
- Gastric or esophagogastric junction adenocarcinoma confirmed by pathology.
- HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplification proven by fluorescent in situ hybridization (FISH) based on pretreatment endoscopic biopsies.
Clinical stage at presentation: cT2-T4b, N+/-, M0 as determined by AJCC staging system, 8th edition.
- The definition of metastatic lymph nodes: a lymph node must be ≥ 10mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) according to the guideline of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1)
- Participants with a performance status of 0 ~ 1 on the Eastern Cooperative Oncology Group (ECOG) within 7 days before the first dose of study treatment.
- Life expectancy ≥ 6 months.
- Agreement of providing pretreatment endoscopic biopsies specimens and surgical specimens for biomarker analysis, as well as the peripheral blood, feces and urine sample.
The functions of the vital organs meet requirements as follow (within 14 days before the first dose of study treatment, participant has not received treatment of recombinant human thrombopoietin or granulocyte stimulating factor):
Hematological function:
- White blood cell count (WBC): 3.5 × 10 ^ 9 / L ~12.0 × 10 ^ 9 / L;
- Absolute neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 / L;
- Platelet count (PLT) ≥ 100 × 10 ^ 9 / L;
- Hemoglobin (Hb) ≥ 90 g / L.
Hepatic function:
- Total bilirubin (TBIL) ≤ 1.5 × ULN (upper limit of normal);
- Aspartate aminotransferase (AST) ≤ 2.5 × ULN;
- Alanine aminotransferase (ALT) ≤ 2.5 × ULN;
- Albumin (ALB) ≥ 30 g / L.
Renal function:
- Creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 60 ml / min for those with creatinine level > 1.5 × ULN.
Coagulation function:
- International normalized ratio (INR) ≤ 1.5;
- Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
Cardiac function:
- The left ventricular ejection fraction (LVEF) value ≥ 55 %, as assessed by echocardiography
- Female of childbearing age must meet requirements: urine or serum pregnancy test must be negative within 7 days before the first dose of study treatment, and she must agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toriplimab, or 210 days after the last dose of trastuzumab, or 180 days after the last dose of chemotherapy, whichever is longer, and should not be breastfeeding. For the male participants must meet requirements: agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toriplimab, or 210 days after the last dose of trastuzumab, or 180 days after the last dose of chemotherapy, whichever is longer).
Exclusion Criteria:
- Prior systemic therapy for treatment of gastric cancer (surgery, chemotherapy, radiotherapy, targeted therapy or immunotherapy).
- Previous or concurrent have other active malignant tumors within the past 5 years (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy).
- Participants with gastric outlet obstruction, or unable for oral take, or severe gastrointestinal bleeding.
- Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV).
- Existence of chronic diarrhea (watery diarrhea: ≥ 5 times per day).
- Participants with active infection within 14 days before the first dose of study treatment which need medical intervention.
- Participants with active tuberculosis.
- Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms.
- Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody.
- Participants who need long-term systemic steroid therapy (> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period.
- Concurrent or previous have severe allergic reaction to any antibody-based drugs.
- Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy.
- Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza.
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Existence of systemic disease that is difficult to control despite treatment with several agents, for example, diabetes mellitus, hypertension, etc.
- Existence of other serious physical or mental diseases or serious laboratory abnormalities that may increase the risk of participating in the study. Participants who were judged unsuitable as subjects of this trial by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Toripalimab plus Trastuzumab with FLOT(5-FU+leucovorin+docetaxel+oxaliplatin)
|
Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery.
The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
Pre-operative treatment 4 cycles and post-operative treatment 4 cycles: Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of pathological complete responses (pCR)
Time Frame: From enrollment to surgery after pre-operative treatment (up to approximately 24 months)
|
Percentage of patients with pCR referring to the total number of enrolled and eligible patients, as evaluated centrally by a reference pathologist.
|
From enrollment to surgery after pre-operative treatment (up to approximately 24 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From enrollment to the end of follow up or death from any cause (up to approximately 60 months)
|
The duration of overall survival (OS) will be determined by measuring the time interval from enrollment to the end of follow up or death from any cause
|
From enrollment to the end of follow up or death from any cause (up to approximately 60 months)
|
Progression-free survival
Time Frame: From enrollment to the end of follow up or the time of disease progression or relapse or death from any cause (up to approximately 60 months)
|
Progression-free survival (PFS) will be defined as the time from enrollment to the end of follow up or the time of disease progression or relapse or death from any cause
|
From enrollment to the end of follow up or the time of disease progression or relapse or death from any cause (up to approximately 60 months)
|
The incidences and types of adverse events (AE) and severe adverse events (SAE)
Time Frame: From enrollment to 90-day after the last dose administration (up to approximately 27 months)
|
The incidences and types of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.3
|
From enrollment to 90-day after the last dose administration (up to approximately 27 months)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Immunological
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Docetaxel
- Trastuzumab
- Oxaliplatin
- Leucovorin
Other Study ID Numbers
- IIT20220076C-R1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-positive Gastric Cancer
-
Triumvira Immunologics, Inc.Merck Sharp & Dohme LLCActive, not recruitingHER2 Positive Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction CancerUnited States, Canada
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
Pieris Pharmaceuticals, Inc.CompletedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid TumorUnited States
-
Pieris Pharmaceuticals, Inc.UnknownHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid TumorUnited States
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
Bavarian NordicActive, not recruitingChordoma | HER2-positive Breast Cancer | HER2-positive Gastric/Gastroesophageal Junction CancerUnited States
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Henan Cancer HospitalRongchang Biopharmaceutical; Zhengda Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHER2-positive Gastric Cancer | Advanced Gastric CarcinomaChina
Clinical Trials on Toripalimab
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Urothelial CarcinomaChina
-
Henan Cancer HospitalUnknownEsophageal Squamous Cell Carcinoma
-
Sun Yat-sen UniversityThe First Affiliated Hospital of Guangzhou Medical University; Guangzhou Panyu...RecruitingStudy of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent ChemoradiotherapySmall Cell Lung Cancer Limited StageChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHead and Neck Squamous Cell CarcinomasChina
-
Shanghai Junshi Bioscience Co., Ltd.Not yet recruitingMelanoma | Breast Cancer | Lung CanceChina
-
Zhejiang Genfleet Therapeutics Co., Ltd.CompletedAdvanced Solid TumorChina, Australia
-
Fudan UniversityUnknownMelanoma Stage IIIB-IVChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, Taiwan, Georgia, United States
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Qianfoshan HospitalRecruiting